Broad availability of low-cost generic pre-exposure prophylaxis drugs could significantly reduce 340B covered entities' revenues on billings for PrEP. | Shutterstock

Much Cheaper PrEP Drugs Could Mean Financial Upheaval for 340B Covered Entities

Correction, Tuesday, May 25, 4:50 p.m. ET – Earlier today, we reported that the wholesale acquisition price for some of the generic PrEP products is now less than $30 per pill. The correct price is less than $30 per bottle. 340B Report regrets the error.

While an important drug’s introduction into the generic market is often celebrated by both providers and patients, generic pre-exposure prophylaxis drugs (PrEP) for patients at risk of contracting HIV could prove a financial disaster for some 340B covered entities.

While an important drug’s introduction into the generic market is often celebrated by both providers and patients, generic pre-exposure prophylaxis drugs (PrEP) for patients at risk of contracting HIV could prove a financial disaster for some 340B covered entities.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer